Highlights
- Entero Healthcare Solutions (NSE: ENTERO) shares gained more than 6% during trading, reaching an intraday high of ₹1,426.30.
- Consolidated revenue from operations increased 38% year-on-year to ₹1,940.50 crore in Q1 FY27.
- Net profit rose 72% year-on-year to ₹52.10 crore from ₹27.80 crore.
- Operating EBITDA increased 94% to ₹97 crore, while EBITDA margin expanded to 5.00%.
- ROCE improved to 21.10% and ROE increased to 20.40% during the quarter.
- The company incorporated Qurovia Lifesciences Private Limited to expand its retail pharmacy business.
Overview
Entero Healthcare Solutions (NSE: ENTERO) is a healthcare products distribution company serving pharmaceutical manufacturers, hospitals, pharmacies and other healthcare providers across India. The company operates through a distribution network designed to connect healthcare product manufacturers with institutional and retail customers, supporting the movement of medicines and healthcare products across multiple markets.
Entero Healthcare Solutions (NSE: ENTERO) remained in focus during Monday's trading session after delivering a strong Q1 FY27 performance. The company recorded substantial growth in revenue and profitability, while operating EBITDA nearly doubled from the year-ago period. The improvement was also accompanied by stronger return ratios and better working-capital efficiency. The stock traded near ₹1,322.10 after opening at ₹1,333.00 and touching an intraday high of ₹1,426.30.
Profit Growth Outpaces Revenue Expansion
Entero Healthcare Solutions (NSE: ENTERO) reported consolidated revenue from operations of ₹1,940.50 crore in Q1 FY27, representing a 38% year-on-year increase. The company continued to expand its top line at a healthy pace, with management indicating that growth remained ahead of the broader Indian pharmaceutical market.
Net profit increased 72% year-on-year to ₹52.10 crore from ₹27.80 crore in the corresponding quarter. The stronger increase in profitability compared with revenue indicates an improvement in the company's operating economics during the quarter.
The company also reported around 40% growth on a like-for-like adjusted basis, with the quarter's performance primarily driven by existing business operations rather than newly completed acquisitions.
Operating Efficiency Drives Margin Improvement
Entero Healthcare Solutions (NSE: ENTERO) reported operating EBITDA of ₹97 crore for Q1 FY27, marking a 94% increase from the year-ago period. EBITDA margin expanded to 5.00% from 3.60%, reflecting a meaningful improvement in operating profitability.
The improvement was supported by the company's efforts to exit certain low-margin legacy business profiles and focus on higher-value opportunities. A greater emphasis on premium business segments helped improve the overall unit economics of the operation.
Higher operating leverage, improved business mix and continued cost discipline are therefore becoming increasingly important components of Entero Healthcare Solutions (NSE: ENTERO)'s earnings profile.
Improved Returns Reflect Better Capital Utilisation
The improvement in operating profitability was accompanied by stronger return ratios. Management highlighted that Return on Capital Employed increased to 21.10%, nearly doubling from the year-ago level, while Return on Equity reached 20.40%.
The improvement in return metrics indicates better utilisation of the company's capital base as profitability increased. For a healthcare distribution business where scale and working-capital management are important, maintaining stronger returns while expanding revenue will remain an important part of the company's financial trajectory.
Entero Healthcare Solutions (NSE: ENTERO) also improved its working-capital efficiency during the quarter, with the working-capital cycle declining to 34.80 days from 49.40 days.
Retail Expansion Adds a New Growth Avenue
Entero Healthcare Solutions (NSE: ENTERO) continues to explore opportunities to expand its healthcare distribution platform and strengthen its presence across different customer segments. The company incorporated Qurovia Lifesciences Private Limited on July 25, 2026, as a step-down subsidiary aimed at expanding its retail pharmacy activities.
The move adds another potential avenue for business expansion while complementing the company's existing healthcare distribution operations. Retail pharmacy provides exposure to a broader healthcare consumption ecosystem and could support diversification as the company develops its network.
The company's ongoing focus on operational scale, customer reach and business mix will remain important as it seeks to sustain the growth momentum recorded in Q1 FY27.
Technical Outlook
Entero Healthcare Solutions (NSE: ENTERO) traded near ₹1,322.10 after opening at ₹1,333.00 and touching an intraday high of ₹1,426.30, while the day's low stood at ₹1,310.00. The stock continues to trade above its 50-day Simple Moving Average of ₹1,186.29, indicating that the broader trend remains positive. The 14-day Relative Strength Index stood at 65.90, suggesting elevated but improving momentum following the recent upward movement.
Key Levels to Watch
Immediate support is placed near ₹1,310.00, followed by ₹1,186.29, which represents the 50-day Simple Moving Average. On the upside, resistance is seen around ₹1,426.30, the day's high. Price action around these levels may provide further indication of the stock's near-term direction.
Summary
Entero Healthcare Solutions (NSE: ENTERO) delivered a strong Q1 FY27 performance, with consolidated revenue rising 38% and net profit increasing 72% year-on-year. Operating EBITDA nearly doubled to ₹97 crore, while the EBITDA margin expanded to 5.00%. The company also reported significant improvements in ROCE, ROE and working-capital efficiency, highlighting better operating and capital utilisation. The incorporation of Qurovia Lifesciences Private Limited adds a potential new avenue for retail pharmacy expansion. From a technical perspective, Entero Healthcare Solutions (NSE: ENTERO) remains above its 50-day Simple Moving Average of ₹1,186.29, while the RSI of 65.90 reflects elevated momentum.
FAQs
Q: Why is Entero Healthcare Solutions (NSE: ENTERO) in focus?
A: Entero Healthcare Solutions (NSE: ENTERO) is in focus after reporting strong Q1 FY27 results, with net profit rising 72%, revenue increasing 38% and operating EBITDA climbing 94%.
Q: How much revenue did Entero Healthcare Solutions (NSE: ENTERO) report in Q1 FY27?
A: Entero Healthcare Solutions (NSE: ENTERO) reported consolidated revenue from operations of ₹1,940.50 crore during Q1 FY27, representing 38% year-on-year growth.
Q: What drove the improvement in Entero Healthcare Solutions (NSE: ENTERO) profitability?
A: Higher operating scale, an improved business mix, the exit from certain low-margin legacy profiles and better operating efficiency supported the improvement in profitability and EBITDA margins.
Q: What should investors monitor going forward?
A: Investors may monitor revenue growth, EBITDA margins, working-capital efficiency, return ratios, retail pharmacy expansion and the company's ability to sustain profitability as the business continues to scale.